Abstracts for conferences can be downloaded by clicking on links

2011

  • Effects of formulation and route of administration on the systemic availability of Ex-RAD®, a new radioprotectant, in preclinical species. Chun AW, Freshwater RE, Taft DR, Gillum AM, Maniar M Biopharmaceutics & Drug Disposition 32: 99-111 (2011).

14th Int'l Congress of Radiation Research, Aug 28-Sept 1, 2011, Warsaw, Poland

  • Effect of ethacrynic acid (EA) on the pharmacokinetics of Ex-RAD® (ON 01210.Na) in the isolated perfused rat liver model (IPRL). Ren C, Tamhane M, Taft DR and Maniar M. Abstract #POS20-20.
  • ON 01210.Na induces SLUG pathway to mitigate radiation-induced hematopoietic toxicity in mice. Datta K, Suman S, Kumar R, Maniar M and Fornace AJ. Abstract #POS23-16.
  • Prophylactic and therapeutic efficacy of a new formulation of ON 01210.Na (Ex-RAD®) after total body radiation in mouse model. Ghosh SP, Kulkarni S, Chakraborty K, Kevin Hieber K, Pessu R, Lombardini ED, Maniar M and Kumar KS. Abstract #POS23-26.

    • ASCO Annual Meeting, June 3-7, 2011, Chicago, IL

    • Final results of a phase 1 study of the combination of a novel cell cycle inhibitor ON 01910.Na with gemcitabine in patients with advanced pancreatic and other solid tumors.W. W. Ma, W. A. Messersmith, G. K. Dy, E. Freas, A. Whitworth, F. Wilhelm, S. G. Eckhardt, A. A. Adjei, A. Jimeno Roswell Park Cancer Institute, Buffalo, NY; University of Colorado Cancer Center, Aurora, CO; University of Colorado Cancer Center, Denver, CO; Roswel Park, Buffalo, NY; Onconova Therapeutics, Inc., Newtown, PA; University of Colorado School of Medicine, Anschutz Medical Campus, Aurora, CO; Division of Medical Oncology, University of Colorado, Denver, Aurora, CO.
    • Final results of a phase 1 dose-escalation study of ON 01910.Na in combination with oxaliplatin in patients with advanced solid tumors.T. Ohnuma, J. F. Holland, S. Goel, E. Wilck, D. Lehrer, M. H. Ghalib, I. Chaudhary, F. Wilhelm, U. Swami, S. Mani Mount Sinai School of Medicine, New York, NY; Montefiore Medical Center, Bronx, NY; Mount Sinai Medical Center, New York, NY; Onconova Therapeutics, Inc., Newtown, PA; Montefiore Cancer Center, Bronx, NY

      • AACR Annual Meeting, April 2-6. 2011, Orlando, FL

      • Targeting cancer with a selective ATP-mimetic inhibitor of polo like kinase-2. Shashidhar S. Jatiani, Stephen C. Cosenza, Vinay K. Billa, M.V. Ramana Reddy, E. Premkumar Reddy. Mount Sinai School of Medicine, New York, NY.
      • Glucuronidation in human colon cancer cells acts as an intrinsic mechanism of resistance against tubulin depolymerizers that are UGT substrates. Stephen C. Cosenza1, Sool Yeon Cho2, Ramana Tantravahi1, Gayatri Panda1, Venket Pallela1, M.V. Ramana Reddy1, John Roboz2, E. Premkumar Reddy1. 1Dept. of Oncological Sciences, Mount Sinai School of Medicine, New York, NY; 2The Tisch Cancer Institute, Mount Sinai School of Medicine, New York, NY
      • RanGAP1•SUMO1 hyperphosphorylation (RGSH) and mitotic arrest by ON 01910.Na, okadaic acid or tubulin agents. Irina Oussenko, James F. Holland, E. Premkumar Reddy, Takao Ohnuma. Mount Sinai School of Medicine, New York, NY.
      • ON015640, a novel anti-cancer agent with tubulin depolymerizing activity. Benjamin S. Hoffman1, Stephen C. Cosenza2, Venkat Palella2, Ramana Reddy2, EP Reddy2. 1Temple University, Philadelphia, PA; 2Mount Sinai School of Medicine, New York, NY.
      • Single-cell network profiling (SCNP) to evaluate the proteomic profiles associated with ON 01910.Na treatment of MDS patients (Pts). Alessandra Cesano1, David Soper1, Steve Banville1, Mai Tran2, Mahesh Seetharam2, Ramesh Kumar3, Francois Wilhelm3, Peter Greenberg2. 1Nodality, Inc., South San Francisco, CA; 2Stanford University School of Medicine, Palo Alto, CA; 3Onconova, Princeton, NJ.

      ACS National Meeting, March 27-31, 2011, Anaheim, CA

      • Potential new agent for refractory lymphomas, ON 013100 esters as a novel class of potent mitotic inhibitors: Synthesis, SAR and target identification. Mallireddigari MR, Pallela VR, Cosenza SC, Divakar SKA, Patti R, Maniar M, Reddy EP, Reddy MVR. ACS National Mtg, Abstract #217.
      • ESTYBON™ (ON 01910.Na) - a clinical stage multi kinase inhibitor: Synthesis, structure activity relationship and biological activity. Pallela VR, Venkatapuram P, Cosenza SC, Mallireddigari MR, Maniar M, Reddy EP, Reddy MVR. ACS National Mtg, Abstract #106.

      2010

      • Discontinuous Drug Binding to Proteins: Binding of an Antineoplastic Benzyl Styryl Sulfone to Albumin and Enzymes in Vitro and in Phase I Clinical Trials. Cho SY, Ohnuma T, Silverman LR, Holland JF and Roboz J. Drug Metab Dispos 38: 1480-1485 (2010).
      • A Non–ATP-Competitive Dual Inhibitor of JAK2V617F and BCR-ABLT315I Kinases: Elucidation of a Novel Therapeutic Spectrum Based on Substrate Competitive Inhibition. Jatiani SS, Cosenza SC, Reddy MVR, Ha JH, Baker SJ, Samanta AK, Olnes MJ, Pfannes L, Sloand EM, Arlinghaus RB, and Reddy EP. Genes & Cancer 1: 331-345 (2010).
      • Design, synthesis and evaluation of (E)-alpha-benzylthio chalcones as novel inhibitors of BCR-ABL kinase. Reddy MVR, Pallela VR, Cosenza SC, Mallireddigari MR, Patti R, Bonagura M, Truongcao M, Akula B, Jatiani SS and Reddy EP. Bioorg Med Chem 18: 2317-2326 (2010).
      • Destabilization of Bcr-Abl/Jak2 Network by a Jak2/Abl Kinase Inhibitor ON044580 Overcomes Drug Resistance in Blast Crisis Chronic Myelogenous Leukemia (CML). Samanta AK, Chakraborty SN, Wang YL, Schlette E, Reddy EP and Arlinghaus RB. Genes & Cancer 1: 346-359 (2010).

      American Society of Hematology, 52nd Annual Meeting, 4-7 December 2010, Orlando, FL

      • Synergistic Effects of a Novel Water-soluble Small Molecule, ON 013105, and Rituximab on Mantle Cell Lymphoma In vitro and In vivo Anil Prasad, PhD, Ashutosh Shrivastava, PhD, Ramana MV Reddy, PhD, Amanda Gillum, PhD, E. PremKumar Reddy, PhD, and Jerome Groopman, MD.
      • Overall Survival in Patients with a Myelodysplastic Syndrome or Acute Myeloid Leukemia Treated With ON 01910.Na Correlates with Bone Marrow Blast Response Lewis R. Silverman, MD, Azra Raza, MD, Elaine Sloand, MD, Peter Greenberg, MD and Francois Wilhelm, MD, PhD.
      • Evaluation of ON01910.Na In Patients with a Myelodysplastic Syndrome(MDS) or Acute Myeloid Leukemia (AML) Relapsed or Refractory to Hypomethylating Agents: A Phase I Study Lewis R Silverman, MD, Shyamala C. Navada, MD, Rosalie Odchimar-Reissig, RN,Vesna Najfeld, PhD, Takao Ohnuma, MD, Francois Wilhelm, MD, PhD., E. Premkumar Reddy, Ph.D. and James F. Holland, MD
      • Treatment of Higher Risk Myelodysplastic Syndrome Patients Unresponsive to Hypomethylating Agents with ON 01910.Na Mahesh Seetharam, MD, Mai Tran, Alice C. Fan, MD, Liwen Xu, PhD, John P. Renschler, 2Dean W. Felsher, MD, PhD, 1Kunju Sridhar, PhD, Francois Wilhelm, MD, PhD and 1Peter L. Greenberg, MD.

      Radiation Research Society 56th Annual Meeting: Sept 25-29, 2010, Maui, HI

      • Recovery from radiation-induced hematopoietic and gastrointestinal sub-syndromes by Ex-RADTM in murine model Ghosh SP, Kulkarni S, Perkins MW, Gambles K, Hieber K, Maniar M, Seed TM and Kumar KS. Radiation Soc Annual Mtg, Abstract #PS1.10 (2010).
      • Radioprotection of human bone marrow by ON 01210.Na (Ex-RAD™) through AKT mediated signaling pathway. Kang AD, Cosenza SC, Reddy MVR and Reddy EP. Radiation Soc Annual Mtg, Abstract #258 (2010).
      • Radioprotection and radiomitigation properties of Ex-RAD® upon oral administration. Maniar M, Kumar R, Moon B-H, Taft DR and Datta K. Radiation Soc Annual Mtg, Abstract #MS701 (2010).
      • Metabolic disposition of Ex-RAD® (ON 01210.Na), a novel radioprotectant. Ren C, Tamhane M, Fegley GJ, Taft DR and Maniar M. Radiation Soc Annual Mtg, Abstract #379 (2010).
      • Disposition of Ex-RAD® (ON 01210.Na), a new radioprotectant, in the isolated perfused rat liver model. Ren C, Tamhane M, Taft DR and Maniar M. Radiation Soc. Annual Mtg, Abstract #531 (2010).

      13th Annual Force Health Protection Conference: Aug 10-13, 2010, Phoenix, AZ

      • Oral Administration of Ex-RAD® - In vivo Efficacy in Radioprotection and Radiomitigation Models. Maniar M, Datta K, Moon B-H and Kumar R. 13th Annual Force Health Protection Conference, Poster (2010).

      AACR: Washington, DC, April 17-21, 2010

      • Multicenter Pharmacokinecit Evaluation of ON 01910.Na, a novel broad-spectrum anticancer agent, in Phase I Single Agent Clinical Trials in Patients with Solid Tumors. Manoj Maniar, Sridhar Mani, Mohammed H Ghalib, Imran Chaudhary, John Roboz, Takao Ohnuma, Suresh Advani, Raghunadh Rao, D Doval, Manmohan Acharya, Edward ORourke, Francois Wilhelm, James F Holland and David Taft
      • ON 01910.Na, a clinical stage anticancer mitotic inhibitor, produces prolonged hyperphosphorylation of RanGAP1•SUMO1 as a potential mechanism of G2/M arrest and apoptosis Irina Oussenko, James F. Holland, E. Premkumar Reddy, Takao Ohnuma.
      • ON 01910.Na, a clinical trial stage multi-kinase inhibitor, induces apoptosis in chronic lymphocytic leukemia (CLL) cells through inhibition of PI3K/AKT and activation of the JNK pathway resulting in NOXA and BIM upregulation Patricia Perez-Galan, Colby Chapman, Xiameng Sun, Federica Gibellini, Poching Liu, Nalini Raghavachari and Adrian Wiestner
      • Proposed Pathway of Disposition of ON 01910.Na, a Novel Clinical Trial Stage Anti-Cancer Agent: Implication of Mrp2 in Biliary Excretion in the Isolated Perfused Rat Liver System. David Taft, Amy Chun, Chen Ren and Manoj Maniar.

      American Chemical Society National Meeting: March 21-25, 2010, San Francisco, CA

      • (Z)-1-Aryl-3-(arylamino)prop-2-en-1-ones: A novel class of antitubulin agents. Akula B, Cosenza SC, Pallela VR, Billa V, Patti R, Reddy EP and Reddy MVR. ACS Annual Mtg, Abstract #MEDI244 (2010).
      • Stereospecific synthesis and biological evaluation of (E) and (Z)-styryl benzylsulfides, sulfoxides, and sulfones. Mallireddigari MR, Cosenza SC, Pallela VR, Reddy EP and Reddy MVR. ACS Annual Mtg, Abstract #MEDI75 (2010).
      • (E)-Styryl-N-aryl carboxamides: Novel antimitotic agents. Pallela VR, Cosenza SC, Natala SR, Mallireddigari MR, Billa V, Patti R, Reddy EP and Reddy MVR. ACS Annual Mtg, Abstract #MEDI255 (2010).
      • N-Aryl-N-(arylsulfonyl)benzamides: Potent mitotic cell cycle inhibitors. Sen S, Dandu VS, Mallireddigari MR, Akula B, Reddy EP and Reddy MVR. ACS Annual Mtg, Abstract #MEDI372 (2010).

      2009

      ASH: New Orleans, December 5-8, 2009

      • The PI3K inhibitor ON 01910.Na Inhibits Critical Survival Pathways in the Tumor Microenvironment and Induces Apoptosis in CLL cells Through Induction of NOXA and BIM. Patricia Perez-Galan, Colby Chapman, Federica Gibellini, Poching Liu, Nalini Raghavachari and Adrian Wiestner.
      • Initial Evaluation of a 48-h Continuous Intravenous Infusion Weekly Regimen of ON 01910.Na in Advanced Myelodysplastic Syndrome (MDS) Azra Raza, MD, Naomi Galili, PhD, Muhammad Shahzad Ali, MD, Fahad Ali, MD, Alyssa Goodman, Samir Ahmed Qasim, MD and Francois Wilhelm, MD, Ph.D.
      • ON 01910.Na Suppresses Cyclin D1 Accumulation in Trisomy 8 Myelodysplastic Syndromes Patients While Decreasing Bone Marrow CD34+ Blast Counts and Aneuploid Clone Size Elaine M Sloand, MD, Matthew J. Olnes, MD, PhD, Naomi Galili, PhD, Aarthi Shenoy, MD, Loretta Pfannes, Francois Wilhelm, MD, Ph.D, Barbara Weinstein, Phillip Scheinberg, MD, Jerome E. Groopman, MD8 and Azra Raza
      • Single Cell Network Profiling (SCNP) to Evaluate the Mechanism of Action of ON 01910.Na,a Novel Clinical Trial Stage Compound D.M. Soper, Y.W. Huang, F. Wilhelm, S. Cosenza, E.P. Reddy, A. Cesano, P.L. Greenberg, W.J. Fantl
      • Radiation protection by a new chemical entity, Ex-RadTM: efficacy and mechanisms. Ghosh SP, Perkins MW, Hieber K, Kulkarni S, Kao TC, Reddy EP, Reddy MVR, Maniar M, Seed T and Kumar KS. Radiat Res 171(2): 173-9 (2009).
      • Evaluation of the novel mitotic modulator ON 01910.Na in pancreatic cancer and preclinical development of an ex vivo predictive assay. Jimeno A, Chan A, Cusatis G, Zhang X, Wheelhouse J, Solomon A, Chan F, Zhao M, Cosenza SC, Reddy MVR, Rudek MA, Kulesza P, Donehower RC, Reddy EP and Hidalgo M. Oncogene 28(4): 610-8 (2009).
      • Styryl sulfonyl compounds inhibit translation of cyclin D1 in mantle cell lymphoma cells. Prasad A, Park IW, Allen H, Zhang X, Reddy MV, Boominathan R, Reddy EP and Groopman JE. Oncogene 28(12):1518-28 (2009).
      • Preclinical pharmacokinetics and in vitro activity of ON 01910.Na, a novel anti-cancer agent. Chun AW, Cosenza SC, Taft DR, and Maniar M. Cancer Chemother Pharmacol 65: 177-186 (2009).

      AACR: Denver, April 18-22, 2009

      • ON 01910.Na, a novel clinical grade PLK-1 inhibitor, selectively induces apoptosis in human B-cell chronic lymphocytic leukemia. Chapman CM, Perez-Galan P & Wiestner A. Abstract 3654 (2009).
      • Identification of a dual JAK-2/BCR-ABL kinase inhibitor for treatment of myeloproliferative disorders. Jatiani SS, Cosenza SC, Pallela VR, Ha JH, Baker SJ, Reddy MVR & Reddy EP. Abstract 3717 (2009).
      • Modulation of Chk1, Chk2, p-Chk2 dimer and p-ATM in cancer cells treated with ON 01910.Na, a clinical stage mitotic inhibitor. Oussenko I, Holland JF, Reddy EP & Ohnuma T. Abstract 3866 (2009).
      • Novel Bcr-abl kinase inhibitors active against T315I imatinib resistant mutation: (Z)-3-benzylideneindolinones: structure activity relationship and biological evaluation. Reddy MVR, Cosenza SC, Billa VK, Pallela VR, Mallireddigari MR & Reddy EP. Abstract 3718 (2009).
      • Pathway-based comparison approach for the identification of responders to the mitotic modulator ON 01910.Na in head and neck cancer (HNC). Tan AC, Anderson R, Frederick B, Raben D & Jimeno A. Abstract 4702 (2009).

      2008

      • Phase I study of ON 01910.Na, a novel modulator of the Polo-like kinase 1 pathway, in adult patients with solid tumors. Jimeno A, Li J, Messersmith WA, Laheru D, Rudek MA, Maniar M, Hidalgo M, Baker SD, & Donehower RC. J Clin Oncol 26(34):5504-10 (2008).
      • Celecoxib and a novel COX-2 inhibitor ON 09310 upregulate death receptor-5 expression via GADD153/CHOP. Q. He, X. Luo, W. Jin, Y. Huang, M.V.R Reddy, E.P. Reddy and M.S. Sheikh. Oncogene, 27, 2656-2660, (2008).
      • Design, Synthesis and Biological Evaluation of (E)-Styryl Benzyl sulfones as Novel Anticancer Agents. M.V. Ramana Reddy, Muralidhar R Mallireddigari, Stephen C Cosenza, Venkat R Pallela, Nabisa M Iqbal, Anthony D. Kang and E. Premkumar Reddy. J.Med. Chem. 51, 86-100, (2008).
      • Design, synthesis, and biological evaluation of 1-(4-sulfamylphenyl)-3-trifluoromethyl-5-indolyl pyrazolines as cyclooxygenase-2 (COX-2) and lipoxygenase (LOX) inhibitors. M.V. Ramana Reddy, Vinay K Billa, Venkat R Pallela, Muralidhar R Mallireddigari, Rengasamy Boominathan, Jerome L Gabriel and E. Premkumar Reddy. Bioorg. Med.Chem, 16, 3907-3916, (2008).

      ASH: San Francisco, December 2008

      • Suppression of Cyclin D 1 (CD1) by ON 01910.Na is associated with decreased survival of trisomy 8 myelodysplastic bone marrow: a potential targeted therapy for trisomy 8 MDS. Shenoy A, Pfannes L, Wilhelm F, Young NS, & Sloand EM. Abstract 1651 (2008).

      ASCO: Chicago, May-June 2008

      • Phase 1 study of ON 01910.Na, a novel polo-like kinase 1 pathway modulator, administered as a weekly 24-hour continuous infusion in patients with advanced cancer. J.M.Vainshtein, M.H.Ghalib, M.Kumar, I.Chaudhary, M.Maniar, D.R.Taft, S.Cosenza, E.P.Reddy, S.Goel, S.Mani.

      AACR: San Diego, April 2008

      • Design, synthesis and biological evaluation of novel, orally available tubulin depolymerizing (E) N-aryl-2-arylethenesulfonamide compounds. M V Ramana Reddy, Stephen C. Cosenza, Venkat R. Pallela, Srinivas R. Natala, Muralidhar R., Mallireddigari, Manoj Maniar, Nabissa M. Iqbal, E Premkumar Reddy. Fels Institute for Cancer Research, Philadelphia, PA, Onconova Therapeutics Inc, Newtown, PA.

      2007

      • Evaluation of novel cell cycle inhibitors in mantle cell lymphoma. I-W. Park, M.V.R Reddy, EP Reddy and JE Groopman. Oncogene, 1-8 (2007)
      • Evaluation of ON 01910.Na, a novel modulator of polo-like kinase 1 (Plk1) pathway, and development of a cyclin-B1-based predictive assay in pancreatic cancer. A. Jimeno, A. Chan, X. Zhang, J. Wheelhouse, A. Solomon, S. C. Cosenza, M.V.R Reddy, M. Rudek, P. Kulesza, E. Reddy, M. Hidalgo. J. Clin. Oncol. 25, No.18S, 3569 (2007).
      • Validation and implementation of a liquid chromatography/tandem mass spectrometry assay to quantitate ON 01910.Na, a mitotic progression modulator, in human plasma. J. Li, M. Zhao, A. Jimeno, P. He, M.V. Ramana Reddy, M. Hidalgo, R. C. Donehower and M.A. Rudek. J. Chromatogr B. 856, 198-204, (2007).

      ASH: Atlanta, December 2007

      • Suppression of Cyclin D1 by on 01910.Na Is Associated with Decreased Survival of Trisomy 8 Myelodyplastic Bone Marrow Progenitors: A Potential Targetted Therapy. Elaine M.Sloand,1 Loretta Pfannes*,1 Ramana Reddy*,2 Premkumar Reddy*,2 Jerome S.Groopman,3 Neal S.Young*.1 'Hematalogy Branch, Divison of Intramural Research, National Heart Lung and Blood Institute, Bethesda, MD USA; 2 Onconova Therapeutics. Lawrenceville, NJ, USA; 3 Experimental Hematology, Harvard University, Boston, MA, USA.

      AACR: Los Angeles, April 2007

      • LB-7 Phase I study of ON 01910.Na, a novel modulator of polo-like kinase 1 (Plk1) pathway, in adult patients with solid tumors. Antonio Jimeno, Jing Li, M.V.Ramana Reddy, E.Premkumar Reddy, Manoj Maniar, Daniel A.Laheru, Wells A.Messersmith, Michelle A.Rudek, Sharyn D.Baker, Manuel Hidalgo, Ross C.Donehower, Johns Hopkins University, Baltimore, MD; Fels Institute for Caner Research and Molecular Biology, Temple University School of Medicine, Philadelphia, PA; Onconova Therapeutics, New Jersey, NJ.

      ASCO: Chicago, June 2007

      • Evaluation of ON 01910.Na, a novel modulator of polo-like kinase 1 (Plk1) pathway, and development of a cyclin-B1-based predictive assay in pancreatic cancer. Author(s): A. Jimeno, A. Chan, X. Zhang, J. Wheelhouse, A. Solomon, S. C. Cosenza, M. Reddy, M. Rudek, P. Kulesza, E. Reddy, M. Hidalgo.

      2006

      ASCO: Atlanta, June 2006:

      • Phase I Study of ON 01910.Na by 3-day continuous infusion (CI) in patients with advanced cancer. T Ohnuma, S.Y. Cho, J. Roboz, J. Jiang, D. Lehrer, L.R. Silverman, J.D. Schwartz, E.P. Reddy; Mount Sinai School of Medicine, New York, NY; Temple University, Philadelphia, PA.
      • Phase I Study of ON 01910.Na, a novel cell cycle inhibitor in adult patients with solid tumors. R.C. Donehower, A. Jimeno, J.Li, K. Galvin, F. Anthony, R. Reddy, W. Messersmity, D. Laheru, S.D. Baker; Johns Hopkins University, Baltimore, MD; Onconova Therapeutics, Lawrenceville, NJ; Fels Institute, Temple University Medical School, Philadelphia, PA.
      • Regression of pre-established intracranial tumor growth by ON 01910.Na, a selective anticancer agent currently in Phase I trials. Christopher S. Gondi, Neelima Kandhukuri, Niranjan Yanamandra, M.V. Ramana Reddy, E.P. Reddy and Jasti Rao: University of Illinois at Peoria. Presentation on June 4th, 2006.

      AACR: Washington, D.C., April 2006:

      • Cross-resistance to ON 01910.Na among Drug-resistant Human tumor cell lines. Adrian Preda, Takao Ohnuma, Jiang, James F. Holland, E. Premkumar Reddy. Mount Sinai School of Medicine, New York, NY, Temple University, Philadelphia, PA
      • Toxicology of a novel small molecule ON 01910.Na on Human Bone Marrow and Leukemic Cells In Vitro. gor Skidan1, Svetlana Zinzar1, M.V. Ramana Reddy2 and E.P. Reddy2, James F. Holland1, Lewis R. Silverman1. Mount Sinai School of Medicine, New York, NY and Fels Institute, Temple University, Philadelphia, PA.
      • Mass Spectrometry of Intact Complexes of Benzyl Styryl Sulfone ON 01910.Na with Albumin using Direct Serum Injection. John Roboz, Sool Yeon Cho, Takao Ohnuma, Jian-Dong Jiang, Yanling Wang, *Stanley Bell, **E. Premkumar Reddy, and James F. Holland. Dept. Medicine, Mount Sinai School of Medicine, New York, NY 10029, *Onconova Therapeutics, Inc., Lawrenceville, NJ 08648, **Fels Institute for Cancer Research, Temple University, Philadelphia, PA, 19140.

      2005

      • Design, synthesis, and biological evaluation of (E)- and (Z)-styryl-2-acetoxyphenyl sulfides and sulfones as cyclooxygenase-2 inhibitors. M.V. Ramana Reddy, M.R. Mallireddigari, V.R. Pallela. Padmavathi.V,R. Boominathan, S.C. bell and E. Premkumar Reddy, Bioorg. Med. Chem, 13, 1715-1723 (2005).
      • A non-ATP-competitive inhibitor of BCR_ABL overrides imatinib resistance. Kiran G, S.J. Baker, S.C. Cosenza, J. Premila, A.D. Kang, K.A. Robell, M.V. Ramana Reddy, and E.Premkumar Reddy. Proc. Natl. Acad. Sci. USA, 102, 1992-1997 (2005).
      • New Coumarin-3(N-Aryl) carboxamides arrest breast cancer cell growth by inhibiting ErbB-2 and ERK1. N.S. Reddy, K. Gumireddi, M.R. Mallireddigari, S.C. Cosenza, P. Venkatapuram, S.C. Bell, E. Premkumar Reddy and M.V. Ramana Reddy, Bioorg.Med.Chem, 13, 3141-3147, (2005).
      • ON 01910, a non-ATP competitive small molecule inhibitor of Plk1 is a potent anticancer agent. K. Gumireddi,, M.V. Ramana Reddy, S.C. Cosenza, R. Boominathan, S.J. Baker, N. Papathi, J. Jiang, J. Holland and E. Premkumar Reddy. Cancer Cell, 7. 275-286, 2005.
      • Sequential reduction and dehydration of phenacyl-(E)-styryl sulfones to asymmetrical (E,E)- bis(styryl)sulfones. M.Mallireddigari, V.R. Pallela, E. premkumar Reddy and M.V. Ramana Reddy. Synthesis, 3639-3643 (2005).

      2004

      • Solvent dependent dehydrating condensation of benzylsulfonyl acetic acids. Reddy, N.S; Reddy, E. Premkumar and M.V. Ramana Reddy. Synthetic Communications, 34, 2691-2695 (2004).
      • Synthesis of new coumarin 3-(N-aryl) sulfonamides and their anticancer activity. N.S. Reddy; M.R.Mallireddigari; S. C. Cosenza; K. Gumireddy; S.C. Bell; E. Premkumar Reddy, M.V. Ramana Reddy. Bioorg. Med. Chem. Lett. 14, 4093-4097 (2004).